Martin "M" Zenni, M.D.

Martin "M" Zenni M.D.

Associate Professor & Medical Director, Cardiovascular Off Campus Outreach Program; Medical Director of Nuclear Cardiology

Department: Department of Medicine
Business Phone: (904) 244-2655
Business Email: martin.zenni@jax.ufl.edu

Board Certifications

  • Internal Medicine
  • Cardiovascular Disease
  • Interventional Cardiology
  • Nuclear Cardiology

Clinical Profile

Specialties
  • Cardiovascular Disease
  • Interventional Cardiology
  • Nuclear Cardiology
Interests
  • Clinical Special Interests: Coronary artery disease, atherosclerosis, hyperlipidemia and cardiac risk assessment; permanent pacemaker and hypothermia therapy for acute myocardial infarction; nuclear cardiology, antiplatelet and anticoagulant therapy
  • Research Special Interests: Coronary artery disease, atherosclerosis, hyperlipidemia and cardiac risk assessment, permanent pacemaker, and hypothermia therapy for acute myocardial infarction; nuclear cardiology, antiplatelet and anticoagulant therapy

Publications

2022
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease.
European heart journal. Cardiovascular pharmacotherapy.8(5):452-461[DOI] 10.1093/ehjcvp/pvab042.[PMID] 34114623.
2022
Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease.
Thrombosis and haemostasis.122(8):1341-1351[DOI] 10.1055/a-1730-8725.[PMID] 34983074.
2022
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.
European heart journal. Cardiovascular pharmacotherapy.8(7):728-737[DOI] 10.1093/ehjcvp/pvac022.[PMID] 35353154.
2022
Swinging heart seen on single-photon emission computed tomography (SPECT).
BMJ case reports.15(6):-[DOI] 10.1136/bcr-2021-246487.[PMID] 35760503.
2021
Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With Cangrelor.
JACC. Cardiovascular interventions.14(21):2410-2412[DOI] 10.1016/j.jcin.2021.07.051.[PMID] 34736741.
2020
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.
Thrombosis and haemostasis.120(1):83-93[DOI] 10.1055/s-0039-1695772.[PMID] 31470444.
2020
Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS-6 Study.
Circulation.142(15):1500-1502[DOI] 10.1161/CIRCULATIONAHA.120.048770.[PMID] 33044856.
2020
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study.
Journal of the American Heart Association.9(8):e015865-[DOI] 10.1161/JAHA.120.015865.[PMID] 32306797.
2020
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing.
JACC. Basic to translational science.5(5):419-428[DOI] 10.1016/j.jacbts.2020.02.009.[PMID] 32478205.
2019
Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine.
JACC. Cardiovascular interventions.12(16):1538-1549[DOI] 10.1016/j.jcin.2019.05.028.[PMID] 31377269.
2019
Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study.
JACC. Basic to translational science.4(7):763-775[DOI] 10.1016/j.jacbts.2019.07.011.[PMID] 31998847.
2019
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Circulation.139(14):1661-1670[DOI] 10.1161/CIRCULATIONAHA.118.038317.[PMID] 30630341.
2018
Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study.
Circulation.137(23):2450-2462[DOI] 10.1161/CIRCULATIONAHA.118.033983.[PMID] 29526833.
2017
Impact of chronic kidney disease on platelet P2Y12 receptor signalling in patients with type 2 diabetes mellitus.
Thrombosis and haemostasis.117(1):201-203[DOI] 10.1160/TH16-08-0594.[PMID] 27786340.
2017
Should endovascular approach be the first line of treatment for retroperitoneal bleeding with hemodynamic shock following percutaneous intervention? A case series.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.90(1):104-111[DOI] 10.1002/ccd.26775.[PMID] 27566914.
2016
A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study.
European heart journal.37(35):2722-30[DOI] 10.1093/eurheartj/ehv744.[PMID] 26848148.
2016
Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.
Journal of the American College of Cardiology.67(17):1994-2004[DOI] 10.1016/j.jacc.2016.02.045.[PMID] 27012781.
2016
Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.
Thrombosis and haemostasis.115(3):622-31[DOI] 10.1160/TH15-06-0467.[PMID] 26633836.
2016
Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors.
Thrombosis and haemostasis.116(6):1060-1069[DOI] .[PMID] 27488362.
2016
Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
Circulation.134(11):780-92[DOI] 10.1161/CIRCULATIONAHA.116.023402.[PMID] 27559041.
2016
Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
JACC. Cardiovascular interventions.9(11):1089-98[DOI] 10.1016/j.jcin.2016.02.039.[PMID] 27013060.
2015
Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.
JACC. Cardiovascular interventions.8(11):1457-1467[DOI] 10.1016/j.jcin.2015.02.030.[PMID] 26404199.
2015
Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.
JACC. Cardiovascular interventions.8(8):1075-1083[DOI] 10.1016/j.jcin.2015.02.022.[PMID] 26117466.
2015
Pooled comparison of regadenoson versus adenosine for measuring fractional flow reserve and coronary flow in the catheterization laboratory.
Cardiovascular revascularization medicine : including molecular interventions.16(5):266-71[DOI] 10.1016/j.carrev.2015.05.011.[PMID] 26242981.
2014
Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study.
Journal of cardiovascular translational research.7(1):53-63[DOI] 10.1007/s12265-013-9535-3.[PMID] 24395495.
2014
Operator radiation exposure and physical discomfort during a right versus left radial approach for coronary interventions: a randomized evaluation.
JACC. Cardiovascular interventions.7(7):810-6[DOI] 10.1016/j.jcin.2013.11.026.[PMID] 24954573.
2014
Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
JACC. Cardiovascular interventions.7(4):426-34[DOI] 10.1016/j.jcin.2013.11.019.[PMID] 24630878.
2013
Effects of Cangrelor in Prasugrel Treated Patients: a Pharmacodynamic in Vitro Investigation
Circulation.128(22, S):-[DOI] .[PMID] .
2013
Operator Radiation Exposure and Physical Discomfort During a Right Versus Left Radial Approach for Coronary Interventions: a Randomized Evaluation
Journal of the American College of Cardiology.61():E1683-[DOI] .[PMID] .
2012
Effects of Pioglitazone On Platelet P2Y12 Mediated Signaling in Clopidogrel Treated Patients With Type 2 Diabetes Mellitus
Journal of the American College of Cardiology.59():E263-[DOI] .[PMID] .
2012
Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus.
Thrombosis and haemostasis.108(5):930-6[DOI] 10.1160/TH12-06-0397.[PMID] 22782352.
2012
Pharmacodynamic Effects of Prasugrel Dosing Regimens in Patients On Maintenance Prasugrel Therapy: Results of a Prospective Randomized Study
Journal of the American College of Cardiology.59():E270-[DOI] .[PMID] .
2012
Pharmacodynamic effects of prasugrel dosing regimens in patients on maintenance prasugrel therapy: results of a prospective randomized study.
Journal of the American College of Cardiology.59(19):1681-7[DOI] 10.1016/j.jacc.2011.12.039.[PMID] 22554598.
2012
Radial Access: Is There An Increased Risk of Operator Radiation Exposure During a Right Versus Left Radial Approach?
Journal of the American College of Cardiology.60():B117-[DOI] .[PMID] .
2011
Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy.
Thrombosis and haemostasis.106(2):253-62[DOI] 10.1160/TH11-01-0041.[PMID] 21614414.
2011
Transradial Approach To Coronary Interventions: How Steep Is the Learning Curve for Trained Interventional Cardiologists?
Journal of the American College of Cardiology.58():B141-B142[DOI] .[PMID] .
2009
Antiplatelet Drug Response Variability and the Role of Platelet Function Testing: a Practical Guide for Interventional Cardiologists
Catheterization and cardiovascular interventions..73(1):1-14[DOI] 10.1002/ccd.21782.[PMID] 19089929.
2009
Clopidogrel-Induced Antiplatelet Effect Assessment By Flow Cytometry and Point-Of-Care Based Assays: Correlation Between Vasp and Verifynow P2Y(12) Testing
Journal of the American College of Cardiology.53():A71-[DOI] .[PMID] .
2009
Evaluation of a Modified Light Transmittance Aggregometry Protocol To Assess P2Y(12) Blockade Induced By Clopidogrel
Journal of the American College of Cardiology.53():A71-[DOI] .[PMID] .
2009
Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients.
Thrombosis research.124(3):318-22[DOI] 10.1016/j.thromres.2008.10.001.[PMID] 19012950.
2008
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
European heart journal.29(18):2202-11[DOI] 10.1093/eurheartj/ehn287.[PMID] 18567918.
2008
A systematic review of outcomes in patients with staged carotid artery stenting and coronary artery bypass graft surgery.
Stroke.39(2):361-5[DOI] 10.1161/STROKEAHA.107.495010.[PMID] 18174484.
2008
Association of Heart Failure Class and Left Ventricular Dyssynchrony Measured By Spect Imaging in Ischemic Systolic Heart Failure Patients
Journal of Cardiac Failure.14(6):S90-[DOI] 10.1016/j.cardfail.2008.06.246.[PMID] .
2008
Association of Ventricular Arrhythmia Therapy and Extent of Scarred Myocardium Measured By Single-Photon Emission Computed Tomography Imaging in Ischemic Systolic Heart Failure Patients
Journal of Cardiac Failure.14(6):S58-[DOI] 10.1016/j.cardfail.2008.06.306.[PMID] .
2008
Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment.
The American journal of cardiology.101(4):440-5[DOI] 10.1016/j.amjcard.2007.09.087.[PMID] 18312754.
2008
Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
Thrombosis and haemostasis.99(1):161-8[DOI] 10.1160/TH07-09-0562.[PMID] 18217149.
2008
Impact of the Degree of Platelet Function On Thrombin Generation Profiles in Patients With Type 2 Diabetes Mellitus
Journal of the American College of Cardiology.51():A193-[DOI] .[PMID] .
2008
Variable histological and ultrasonic characteristics of restenosis after drug-eluting stents.
International journal of cardiology.130(3):444-8[DOI] 10.1016/j.ijcard.2007.08.143.[PMID] 18199506.
2007
Anatomical and physiologic assessments in patients with small coronary artery disease: final results of the Physiologic and Anatomical Evaluation Prior to and After Stent Implantation in Small Coronary Vessels (PHANTOM) trial.
American heart journal.153(2):296.e1-7[DOI] .[PMID] 17239692.
2007
Quantitative magnetic resonance perfusion imaging detects anatomic and physiologic coronary artery disease as measured by coronary angiography and fractional flow reserve.
Journal of the American College of Cardiology.50(6):514-22[DOI] .[PMID] 17678734.
2007
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Circulation.115(6):708-16[DOI] .[PMID] 17261652.
2006
Intravascular ultrasound characterization of the "black hole" phenomenon after drug-eluting stent implantation.
The American journal of cardiology.97(2):203-6[DOI] .[PMID] 16442364.
2005
Sirolimus-eluting stents for treatment of complex bypass graft disease: insights from the SECURE registry.
The Journal of invasive cardiology.17(8):396-8[DOI] .[PMID] 16079441.
2004
Multiple plaque morphologies in a single coronary artery: insights from volumetric intravascular ultrasound.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.61(3):376-80[DOI] .[PMID] 14988899.
2004
Synergistic use of sirolimus-eluting stents and intravascular ultrasound for the treatment of unprotected left main and vein graft disease.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.61(3):368-75[DOI] .[PMID] 14988898.
2003
Debulking does not benefit patients undergoing intracoronary beta-radiation therapy for in-stent restenosis: insights from the START trial.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.58(3):331-5[DOI] .[PMID] 12594697.
2002
Intravascular ultrasound catheter entrapment after coronary artery stenting.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.57(2):229-33[DOI] .[PMID] 12357527.

Office Information

Academic Office
5th Floor, Ambulatory Care Center
655 West 8th Street, C35
Jacksonville, FL 32209
(904) 244-3101
martin.zenni@jax.ufl.edu
Administrative Manager
Erika Jackson
(904) 244-2655
erika.jackson@jax.ufl.edu

Education

Medical Degree
1986 · University of Chicago Pritzker School of Medicine, Chicago, IL, USA
Internal Medicine Residency
1989 · Tufts-New England Medical Center, Boston, MA, USA
Cardiovascular Disease Fellowship
1992 · Harvard Medical School, Boston, MA, USA
Interventional Cardiology Fellowship
1993 · Harvard Medical School, Boston, MA, USA